Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

Author(s): Domenico Ribatti, Angelo Vacca

Journal Name: Letters in Drug Design & Discovery

Volume 1 , Issue 2 , 2004

Become EABM
Become Reviewer
Call for Editor


Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.

Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [135 - 136]
Pages: 2
DOI: 10.2174/1570180043485491
Price: $65

Article Metrics

PDF: 3